Member Info for KUMS

now.

Morning all. Let's remind new investors that Woodford has large investment at 10p. I am sure they will try to get to this to that sp for starters. That's a good rise from this bottom.

went up nicely after my posting. If we think sp will do what we say then we would not be posting here. We would have better things to do. Having good investment in OPTI at 16p after selling here, sold some at 70p and profit went in here and am up 3% on that money here. So if things are going to go bad or are not comfortable, then best to sell and make money elsewhere. So today is today and who knows about tomorrow. So make money while you can and take profit or small loss before things go haywire. So as they say DYOR! It's what YOU decide and it's YOUR money. Stay HAPPY!

Let's see 12p that we saw not long ago.

I am BACK and hope to make more money! No point sitting back and seeing money erode away. Did manage to get sp up from 5p to 12p so it was a success! Hope to see it happen again and will be happy with 100% rise!

buys have gone thro. Looking good to be in at bottom so bought some now & back in here again! We have seen 12p before so that would be 100% up from here for starters.

sellers inside 8p cleared. Now let's see 10p+

now have buy rating!

as large buys have taken up the stock yesterday. We should see good rise once people start to get in.

now.

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: "I am pleased with the progress we are making in line with our strategy. The expansion of our two manufacturing sites and the laboratories at Windrush Court is progressing well and we are looking forward soon to the approval of the new Yarnton site for GMP manufacture. We are also working hard on preparing OXB-102 and OXB-202 for their next clinical studies, which we are planning to initiate in 2016, and identifying the development path for OXB-201. The Group continues to be recognised for its IP and expertise and continues to have strong commercial relationships with Sanofi, Novartis and GSK. I was pleased that GSK have recently re-emphasised the value of our LentiVector® platform by exercising their options to take a licence for two rare orphan disease indications. Our revenue and other income is now beginning to grow in line with our expectations with July to October being well ahead of the first four months of the year."

Back in here now. Good rise today.

Negotiated trade only. Another big buy in red showing up.

now for starters.

After seeing those two big buys today & Zak Mir's recent chart, I am back in here. No doubt, we will see plenty of news going forward. So for me, I think starting from this low, there is good gains to be made.

In a statement, Peter Rigg, chairman of MXC, said: “We know Gavin well having supported him during the build of Accumuli - he has proven management track record. Gavin’s a great addition as we continue to build out our team to support our growing deal flow.”

“I am very excited about getting this role," he told CRN. "I have worked with them [Weaver and Smith] in a different guise when they were a strategic partner to our business [Accumuli]. My new role is to find opportunities for MXC to invest capital in. They do a remarkable job here and if you look at them today, their role is as a merchant bank focusing on the TMT [technology, media & telecoms] sector. “Not only do they find investment opportunities for people looking for capital investment, but also for people that can become strategic partners to help create value for their business. We want to help companies build value.”

http://www.channelweb.co.uk/crn-uk/news/2432964/lyons-sinks-claws-into-new-finance-house-role

share buy earlier today at 3.03p & CODE 2!

This will move and it's just a matter of time. Big buyers have been buying upto 3.20p! Just like CTP, it better to take a position before the take off imo. I applied same scenario in other shares and it has paid off handsomely.